Furthermore, by establishing the favorable diuretic profile of SGLT2 inhibitors in managing volume status in heart failure patients, future research can also be considered with respect to SGLT2 inhibitors as an antihypertensive agent among patients without DM. This evidence concerns the gene SLC5A2 and diabetes mellitus.